Alnylam Sees Opportunity in Turning Genes On, And Off

9/5/08Follow @xconomy

(Page 2 of 2)

“Although the technology is at an early stage and much remains to be learned and validated about the mechanisms involved, we do believe that it shows the potential to become a powerful approach to RNA-based therapeutics,” said Michael King, an analyst with Rodman & Renshaw, in a note to clients last month about Alnylam’s venture into RNAa.

The RNAa work is being done with the same type of molecules used for RNAi—RNA strands which are 21 nucleotides, or chemical units, in length, Maraganore says. The company has obtained eight patents which it considers critical to the field, and like with RNAi, it hopes to essentially set up a toll booth for other companies who want to develop drugs using the technology. “If the science progresses as well as we hope, it will enable us to do deals,” with large drugmakers, Maraganore says.

The early work in RNAa dates back to 2004 in Fred Gage‘s lab at the Salk Institute in San Diego. He showed that double-stranded RNA molecules could prompt genes to produce proteins, Maraganore says. “People were scratching their heads at the time,” Maraganore says. “People viewed it as interesting, but probably some artifact that was not reproducible.”

Two years later, Long-Cheng Li of UCSF showed that a double-stranded RNA could stimulate significant activation of the P21 gene that produced anti-tumor activity in bladder cancer cells. Last year, David Corey of the University of Texas-Southwestern Medical Center in Dallas showed in Nature Chemical Biology that “activating RNAs can predictably manipulate physiologically relevant cellular pathways,” according to King, the Rodman & Renshaw analyst.

For now, Alnylam is looking to test some of its ideas about RNAa with academic collaborators, including Corey’s lab and Li’s lab. Regulators will need to be convinced the approach is safe before trials are allowed in humans. Maraganore didn’t provide a date, but says “it could be a few years” before the company enters human trials with an RNAa-based drug. By that time, maybe RNAa will be the hot new technology ready to push RNAi off the covers of the scientific journals.

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.